Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study (Q56971945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

0 references

1 reference

peripheral neuropathy

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Marina Martello

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Luca Baldini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Iacopo Peccatori

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Alessandro Gozzetti

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Guido Cavaletti

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Michele Cavo

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

19

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Paola Tacchetti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Carolina Terragna

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Monica Galli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Elena Zamagni

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Maria Teresa Petrucci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Annalisa Pezzi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Patrizia Tosi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Miriana Ruggieri

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Lucia Pantani

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Antonio Lazzaro

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Francesca Elice

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Serena Rocchi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

17 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Hematology

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

1085-1091

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

Neurological aspects of multiple myeloma and related disorders

13 March 2020

cites work

1 reference

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

21 January 2018

1 reference

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

21 January 2018

1 reference

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

21 January 2018

1 reference

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

21 January 2018

1 reference

21 January 2018

1 reference

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

21 January 2018

1 reference

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

21 January 2018

1 reference

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

21 January 2018

1 reference

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

21 January 2018

1 reference

Thalidomide-induced neuropathy: a ganglionopathy?

21 January 2018

1 reference

Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma

21 January 2018

1 reference

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

21 January 2018

1 reference

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines

21 January 2018

1 reference

Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.

21 January 2018

1 reference

Immune-mediated neuropathies in myeloma patients treated with bortezomib

21 January 2018

1 reference

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

21 January 2018

1 reference

Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons

21 January 2018

1 reference

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

21 January 2018

1 reference

Genetic variation associated with bortezomib-induced peripheral neuropathy

21 January 2018

1 reference

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

21 January 2018

1 reference

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

21 January 2018

1 reference

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

21 January 2018

1 reference

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

21 January 2018

1 reference

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

21 January 2018

1 reference

Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

Progression of paclitaxel-induced neuropathy following discontinuation of treatment

21 January 2018

1 reference

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

21 January 2018

1 reference

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

21 January 2018

1 reference

Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients

21 January 2018

1 reference

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity

21 January 2018

1 reference

Proteasome inhibition arrests neurite outgrowth and causes "dying-back" degeneration in primary culture

21 January 2018

1 reference

Constitutively expressed catalytic proteasomal subunits are up-regulated during neuronal differentiation and required for axon initiation, elongation and maintenance.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23835

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25159313%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference